Last updated: February 15, 2026
Overview
NDC 00406-0807 corresponds to a biosimilar product, likely a biosimilar version of a well-established biologic therapeutic. The specific product is the biosimilar of Remicade (Infliximab), a monoclonal antibody treating autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
Current Market Context
- Market size: The infliximab market size was valued at approximately $9 billion in 2022 globally and is projected to grow at a compound annual growth rate (CAGR) of 6.5% through 2027, driven by biosimilar entry, patent expirations, and cost-containment efforts.
- Key competitors: Remicade's patent expiry in key markets like the U.S. and EU prompted multiple biosimilar entries, including agents approved by the FDA and EMA.
- Biosimilar landscape: As of 2023, more than 8 biosimilars of infliximab are approved or pending approval, with several substitutable options available, intensifying competitiveness and driving price reductions.
Market Penetration Factors
- Healthcare policies: Favor biosimilar adoption due to cost savings. Many countries have policies incentivizing biosimilar use over reference biologics.
- Physician acceptance: Growing confidence in biosimilars, but some residual hesitancy remains, especially in prescribing versus innovator biologics.
- Pricing dynamics: Biosimilars typically price 15-30% below originator biologics. Market share for biosimilars reaching 50-60% within 3-5 years post-launch is common in mature markets.
Price Projections
| Year |
Estimated Price per Vial (USD) |
Market Share |
Revenue Estimate (USD, billions) |
| 2023 |
$1,000 - $1,200 (initial launch) |
10-15% |
$2.1 billion* |
| 2024 |
$900 - $1,100 |
25-35% |
$3.2 billion* |
| 2025 |
$800 - $1,000 |
40-50% |
$4.5 billion* |
| 2026 |
$750 - $950 |
55-60% |
$5.8 billion* |
| 2027 |
$700 - $900 |
60-65% |
$6.9 billion* |
* Revenue estimates assume annual treatment volume consistent with existing infliximab use, dose frequency, and patient population estimates.
Pricing Factors Impacting Projections
- Manufacturing costs: Biosimilar production costs are approximately 30-50% less than originator biologics, enabling competitive pricing.
- Regulatory environment: Ease of approval, especially in regions with expedited pathways, can accelerate market entry and price reductions.
- Market dynamics: Higher market penetration correlates with lower prices due to increased competition and substitution policies.
Risks & Opportunities
- Risks: Patent litigations, supply chain disruptions, slow physician adoption, and regulatory delays.
- Opportunities: Expanding indications, developing export markets, and leveraging contracting strategies in institutional and hospital settings.
Competitive Analysis
| Approach |
Strengths |
Challenges |
| Price leadership |
Higher market share, volumes |
Margin compression, price erosion |
| Differentiation |
Unique formulations, delivery modes |
Higher R&D costs, regulatory hurdles |
Conclusion
The market for biosimilar infliximab, represented by NDC 00406-0807, is poised for significant growth with declining prices over the next five years. Initial prices at launch are expected around $1,000-$1,200 per vial in 2023, decreasing as market share increases. By 2027, prices could fall below $750, with revenues approaching nearly $7 billion globally.
Key Takeaways
- Biosimilar infliximab market expands rapidly due to patent expirations and policy incentives.
- Price declines of 20-30% are typical within three years of market entry.
- Revenue growth depends heavily on market penetration, regulatory approval speed, and physician adoption.
- Competitive pressure will likely push prices downward, but margins could stabilize due to volume increases.
- Emerging markets and indication expansion offer additional revenue channels.
FAQs
-
What is the typical price difference between biosimilar infliximab and the originator?
Biosimilars are generally priced 15-30% below the reference biologic.
-
How long does it usually take for biosimilars to reach significant market share?
Generally, within 3-5 years post-launch, biosimilars can capture 50-60% market share in mature regions.
-
What factors influence the price trajectory of biosimilar infliximab?
Regulatory approval timelines, competitive landscape, healthcare policies, and physician acceptance.
-
Are biosimilar prices stable after initial market entry?
Prices tend to decline further with increased market penetration and competition, stabilizing once a dominant biosimilar gains acceptance.
-
How do regional policies affect biosimilar pricing?
Regions with policies promoting biosimilar substitution and incentivizing cost savings typically see faster price reductions and higher adoption rates.
Sources
[1] Evaluate Pharma, "Global Biosimilar Market Report," 2022
[2] IQVIA, "Biologic and Biosimilar Market Dynamics," 2023
[3] FDA, "Infliximab (Remicade) biosimilar approvals," 2023
